DCP1A Antibody
Description
What is DCP1A Antibody?
DCP1A antibodies are immunoreagents designed to detect and quantify the DCP1A protein, which facilitates mRNA decapping by interacting with DCP2 and other cofactors . These antibodies are used across multiple platforms, including Western blot (WB), immunofluorescence (IF), ELISA, and immunohistochemistry (IHC), to investigate DCP1A's roles in:
-
mRNA degradation: Essential for normal mRNA turnover and nonsense-mediated decay .
-
P-body dynamics: Regulates processing body formation and stress granule assembly .
-
Cancer progression: Correlates with tumor aggressiveness and patient prognosis .
Molecular Mechanisms
-
EVH1 Domain Function: The N-terminal EVH1 domain of DCP1A enhances DCP2’s mRNA-binding affinity, critical for decapping efficiency .
-
Redundancy with DCP1B: DCP1A and DCP1B exhibit functional overlap in general mRNA decay but regulate distinct biological pathways .
-
PKR Activation: Overexpression of DCP1A induces eIF2α phosphorylation via protein kinase R (PKR), linking mRNA decay to innate immunity .
Clinical Significance
-
Cancer Biomarker:
-
Pan-Cancer Analysis: Elevated DCP1A levels correlate with advanced tumor stage and metastasis in digestive system cancers (e.g., CHOL, COAD) .
Validation Data
-
Western Blot: Detects endogenous DCP1A at ~70 kDa in human, mouse, rat, and pig samples .
-
Immunofluorescence: Localizes DCP1A to cytoplasmic P-bodies under stress conditions .
-
Knockout Controls: Specificity confirmed using DCP1A-deficient HEK-293 cell lines .
Functional and Clinical Applications
-
Diagnostic Use: High DCP1A expression in colorectal cancer tissues predicts deeper invasion and lymph node metastasis (P = 0.008) .
-
Therapeutic Target: siRNA-mediated DCP1A knockdown reduces tumor growth in vitro, suggesting potential for RNA-based therapies .
-
Pathway Analysis: DCP1A modulates TGF-β and MAPK signaling, influencing cell proliferation and stress responses .
Technical Considerations
Product Specs
Target Background
- Overexpression of DCP1A has been linked to malignant melanoma. PMID: 29076924
- Studies indicate that overexpressed Dcp1a and GW182 can form distinct cytoplasmic aggregates and play distinct roles in the miRNA pathway. PMID: 28488892
- The E3 ligase TRAF6 interacts with DCP1A and indirectly regulates its phosphorylation, expression of decapping factors, and gene-specific mRNA decay. PMID: 27315556
- The single nucleotide polymorphism (SNP) DCP1A rs11551405 may have a prognostic impact on the survival of patients with coronary microvascular disease (CM). PMID: 27578485
- The assembly of EDC4 and Dcp1a into processing bodies is crucial for the translational regulation of IL-6. PMID: 25970328
- Phosphorylation at serine 315, serine 319, and threonine 321 of DCP1A modulates IL-8 expression during respiratory syncytial virus infection. PMID: 25796077
- Data suggests that DCP2 activation by DCP1 occurs preferentially on the EDC4 scaffold, potentially coupling DCP2 activation by DCP1 with 5'-to-3' mRNA degradation by XRN1 in human cells. PMID: 24510189
- Malin plays a regulatory role in the recruitment of mRNA-decapping enzyme 1A (Dcp1a) to processing bodies. PMID: 23131811
- hDcp1a contributes to the control of processing body dynamics during the cell cycle through phosphorylation. PMID: 23300942
- Research reveals DCP1A as a multifunctional regulator of mRNA expression, suggesting a role for JNK kinase phosphorylation in controlling the subcellular localization of DCP1A in response to stress or inflammatory stimuli. PMID: 21859862
- Evidence shows the presence of P-body-like foci in mouse oocytes, as indicated by the presence of Dcp1a and the colocalization of RNA-associated protein 55 (RAP55) and the DEAD box RNA helicase Rck/p54. PMID: 19812249
- Overexpression of wild-type SMIF enhanced the expression of TGFbeta/BMP regulated genes, while a dominant-negative SMIF mutant suppressed their expression. PMID: 11836524
- These findings suggest that a human decapping complex containing decapping enzymes hDcp1a and hDcp2 may be recruited to mRNAs containing premature termination codons by the hUpf proteins. PMID: 12417715
Q&A
DCP1A Antibody: Frequently Asked Questions for Academic Research
Advanced Research Questions
How to resolve contradictions in DCP1A expression data across cancer studies?
Discrepancies may arise from:
-
Tumor heterogeneity: Use single-cell RNA sequencing or spatial transcriptomics to assess subpopulations .
-
Post-translational regulation: Perform cycloheximide chase assays to compare protein turnover rates vs. mRNA levels .
-
Antibody batch variability: Validate findings with independent clones (e.g., Abcam ab47811 vs. Santa Cruz sc-100896) .
What structural features of DCP1A impact antibody performance in cryo-EM studies?
-
Trimerization dependency: DCP1A forms asymmetric trimers to interact with DCP2; antibodies targeting the trimer interface (residues 300–420) may disrupt complex assembly .
-
Conformational flexibility: Use negative-stain EM to pre-screen antibodies for epitope accessibility in open vs. closed states .
How to design experiments probing DCP1A’s role in mRNA decapping vs. non-canonical functions?
-
Decapping-specific assays: Measure decay of capped reporter mRNAs (e.g., luciferase) in DCP1A-depleted cells .
-
Non-canonical pathways: Use ribosome profiling to assess translational arrest in cells expressing GFP-Dcp1a-ΔNTD (defective in decapping but retains RNA binding) .
Methodological Considerations
How to optimize co-IP protocols for studying DCP1A-DCP2 interactions?
What controls are critical for DCP1A IHC in clinical samples?
-
Negative controls: Adjacent normal tissue or isotype-matched IgG.
-
Quantitative thresholds: Define “high expression” using H-scores (e.g., ≥50% staining intensity in ≥30% cells) .
-
Pathological validation: Correlate with lymph node metastasis and TNM stage .
Data Interpretation Challenges
Why might DCP1A overexpression show both pro-tumor and tumor-suppressive effects?
-
Context-dependent roles: In colorectal cancer, high DCP1A correlates with poor prognosis , while in glioblastoma, decapping may reduce oncogenic mRNA stability.
-
Off-target effects: Overexpression may disrupt P-body dynamics, altering non-DCP1A-dependent RNA regulons .
